[1]
|
Herrington, W.G., Savarese, G., Haynes, R., Marx, N., Mellbin, L., Lund, L.H., et al. (2021) Cardiac, Renal, and Meta-bolic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: A Position Paper from the European Society of Cardiology Ad-Hoc Task Force on Sodium-Glucose Co-Transporter 2 Inhibitors. European Journal of Heart Failure, 23, 1260-1275. https://doi.org/10.1002/ejhf.2286
|
[2]
|
McDonagh, T.A., Metra, M., Adamo, M., Gardner, R.S., Baumbach, A., Böhm, M., et al. (2021) 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal, 42, 3599-3726.
https://doi.org/10.1093/eurheartj/ehab670
|
[3]
|
Cinti, F., Moffa, S., Impronta, F., Cefalo, C.M., Sun, V.A., Sorice, G.P., Mezza, T. and Giaccari, A. (2017) Spotlight on Ertugliflozin and Its Potential in the Treatment of Type 2 Diabetes: Evidence to Date. Drug Design, Development and Therapy, 11, 2905-2919. https://doi.org/10.2147/DDDT.S114932
|
[4]
|
Pitt, B., Bhatt, D.L. and Metra, M. (2022) Does SGLT1 Inhibition Add to the Benefits of SGLT2 Inhibition in the Prevention and Treatment of Heart Failure? European Heart Journal, 43, 4754-4757.
https://doi.org/10.1093/eurheartj/ehac417
|
[5]
|
Uthman, L., Homayr, A., Juni, R.P., Spin, E.L., Kerindongo, R., Boomsma, M., et al. (2019) Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells. Cellular Physiology and Biochemistry, 53, 865-886.
https://doi.org/10.33594/000000178
|
[6]
|
Endemann, D.H. and Schiffrin, E.L. (2004) Endothelial Dysfunction. Journal of the American Society of Nephrology, 15, 1983-1992. https://doi.org/10.1097/01.ASN.0000132474.50966.DA
|
[7]
|
Patel, A.R., Kuvin, J.T., Pandian, N.G., Smith, J.J., Udelson, J.E., Mendelsohn, M.E., Konstam, M.A. and Karas, R.H. (2001) Heart Failure Etiology Affects Peripheral Vascular Endothelial Function after Cardiac Transplantation. Journal of the American College of Cardiology, 37, 195-200. https://doi.org/10.1016/S0735-1097(00)01057-3
|
[8]
|
Gaspari, T., Spizzo, I., Liu, H., Hu, Y., Simpson, R.W., Widdop, R.E. and Dear, A.E. (2018) Dapagliflozin Attenuates Human Vascular Endothelial Cell Activation and Induces Vasorelaxation: A Potential Mechanism for Inhibition of Atherogenesis. Diabetes and Vascular Disease Research, 15, 64-73. https://doi.org/10.1177/1479164117733626
|
[9]
|
Mancini, S.J., Boyd, D., Katwan, O.J., Strembitska, A., Almabrouk, T.A., Kennedy, S., Palmer, T.M. and Salt, I.P. (2018) Canagliflozin Inhibits Interleukin-1β-Stimulated Cyto-kine and Chemokine Secretion in Vascular Endothelial Cells by AMP-Activated Protein Kinase-Dependent and -Independent Mechanisms. Scientific Reports, 8, Article No. 5276. https://doi.org/10.1038/s41598-018-23420-4
|
[10]
|
Juni, R.P., Kuster, D.W.D., Goebel, M., Helmes, M., Musters, R.J.P., van der Velden, J., Koolwijk, P., Paulus, W.J. and van Hinsbergh, V.W.M. (2019) Cardiac Microvascular Endo-thelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin. JACC: Basic to Translational Science, 4, 575-591.
https://doi.org/10.1016/j.jacbts.2019.04.003
|
[11]
|
Uthman, L., Nederlof, R., Eerbeek, O., Baartscheer, A., Schu-macher, C., Buchholtz, N., Hollmann, M.W., Coronel, R., Weber, N.C. and Zuurbier, C.J. (2019) Delayed Ischaemic Contracture Onset by Empagliflozin Associates with NHE1 Inhibition and Is Dependent on Insulin in Isolated Mouse Hearts. Cardiovascular Research, 115, 1533-1545.
https://doi.org/10.1093/cvr/cvz004
|
[12]
|
Baker, H.E., Kiel, A.M., Luebbe, S.T., Simon, B.R., Earl, C.C., Regmi, A., Roell, W.C., Mather, K.J., Tune, J.D. and Goodwill, A.G. (2019) Inhibition of Sodium-Glucose Cotransporter-2 Pre-serves Cardiac Function during Regional Myocardial Ischemia Independent of Alterations in Myocardial Substrate Utili-zation. Basic Research in Cardiology, 114, Article No. 25. https://doi.org/10.1007/s00395-019-0733-2
|
[13]
|
Philippaert, K., Kalyaanamoorthy, S., Fatehi, M., Long, W., Soni, S., Byrne, N.J., Barr, A., et al. (2021) Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodi-um/Glucose Cotransporter 2 Inhibitor Empagliflozin. Circulation, 143, 2188-2204. https://doi.org/10.1161/CIRCULATIONAHA.121.053350
|
[14]
|
Azam, M.A., Chakraborty, P., Si, D., Du, B., Massé, S., Lai, P.F.H., Ha, A.C.T. and Nanthakumar, K. (2021) Anti-Arrhythmic and Inotropic Effects of Empagliflozin Following Myocardial Ischemia. Life Sciences, 276, Article ID: 119440. https://doi.org/10.1016/j.lfs.2021.119440
|
[15]
|
Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., Leslie, B. and List, J. (2013) Dapagliflozin a Glucose-Regulating Drug with Diuretic Properties in Subjects with Type 2 Diabetes. Diabetes, Obesity and Metabolism, 15, 853-862.
https://doi.org/10.1111/dom.12127
|
[16]
|
Connelly, K.A., Zhang, Y., Visram, A., Advani, A., Batchu, S.N., Desjardins, J.F., Thai, K. and Gilbert, R.E. (2019) Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure with Preserved Ejection Fraction. JACC: Basic to Translational Science, 4, 27-37. https://doi.org/10.1016/j.jacbts.2018.11.010
|
[17]
|
Byrne, N.J., Parajuli, N., Levasseur, J.L., Boisvenue, J., Beker, D.L., Masson, G., Fedak, P.W.M., Verma, S. and Dyck, J.R.B. (2017) Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure. JACC: Basic to Translational Science, 2, 347-354.
https://doi.org/10.1016/j.jacbts.2017.07.003
|
[18]
|
Shi, L., Zhu, D., Wang, S., Jiang, A. and Li, F. (2019) Dapagli-flozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload. American Journal of Hypertension, 32, 452-459. https://doi.org/10.1093/ajh/hpz016
|
[19]
|
Verma, S., Garg, A., Yan, A.T., Gupta, A.K., Al-Omran, M., Sabongui, A., Teoh, H., Mazer, C.D. and Connelly, K.A. (2016) Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals with Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial? Diabetes Care, 39, e212-e213. https://doi.org/10.2337/dc16-1312
|
[20]
|
Tsapas, A., Karagiannis, T., Kakotrichi, P., Avgeri-nos, I., Mantsiou, C., Tousinas, G., Manolopoulos, A., Liakos, A., Malandris, K., Matthews, D.R. and Bekiari, E. (2021) Comparative Efficacy of Glucose-Lowering Medications on Body Weight and Blood Pressure in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes, Obesity and Metabolism, 23, 2116-2124. https://doi.org/10.1111/dom.14451
|
[21]
|
McGuire, D.K., Shih, W.J., Cosentino, F., Charbonnel, B., Cherney, D.Z.I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., Gantz, I., Terra, S.G., Masiukiewicz, U. and Cannon, C.P. (2021) Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes: A Meta-Analysis. JAMA Cardiology, 6, 148-158. https://doi.org/10.1001/jamacardio.2020.4511
|
[22]
|
Zheng, C., Lin, M., Chen, Y., Xu, H., Yan, L. and Dai, H. (2021) Effects of Sodium-Glucose Cotransporter Type 2 Inhibitors on Cardiovascular, Renal, and Safety Outcomes in Patients with Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials. Cardiovascular Diabetology, 20, Article No. 83.
https://doi.org/10.1186/s12933-021-01272-z
|
[23]
|
Gilbert, R.E. and Connelly, K.A. (2019) Reduction in the Inci-dence of Myocardial Infarction with Sodium-Glucose Linked Cotransporter-2 Inhibitors: Evident and Plausible. Cardio-vascular Diabetology, 18, Article No. 6.
https://doi.org/10.1186/s12933-019-0812-6
|
[24]
|
Wright, E.M., Loo, D.D. and Hirayama, B.A. (2011) Biology of Human Sodium Glucose Transporters. Physiological Reviews, 91, 733-794. https://doi.org/10.1152/physrev.00055.2009
|
[25]
|
Uhlén, M., Fagerberg, L., Hallström, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., et al. (2015) Proteomics. Tissue-Based Map of the Human Proteome. Science, 347, Article ID: 1260419. https://doi.org/10.1126/science.1260419
|
[26]
|
Tsimihodimos, V., Filippas-Ntekouan, S. and Elisaf, M. (2018) SGLT1 Inhibition: Pros and Cons. European Journal of Pharmacology, 838, 153-156. https://doi.org/10.1016/j.ejphar.2018.09.019
|
[27]
|
Bell, R.M. and Yellon, D.M. (2018) SGLT2 Inhibitors: Hypoth-eses on the Mechanism of Cardiovascular Protection. The Lancet Diabetes & Endocrinology, 6, 435-437. https://doi.org/10.1016/S2213-8587(17)30314-5
|
[28]
|
Kanwal, A., Nizami, H.L., Mallapudi, S., Putcha, U.K., Mo-han, G.K. and Banerjee, S.K. (2016) Inhibition of SGLT1 Abrogates Preconditioning-Induced Cardioprotection against Ischemia-Reperfusion Injury. Biochemical and Biophysical Research Communications, 472, 392-398. https://doi.org/10.1016/j.bbrc.2016.02.016
|
[29]
|
Cefalo, C.M.A., Cinti, F., Moffa, S., Impronta, F., Sorice, G.P., Mezza, T., Pontecorvi, A. and Giaccari, A. (2019) Sotagliflozin, the First Dual SGLT Inhibitor: Current Outlook and Perspectives. Cardiovascular Diabetology, 18, Article No. 20. https://doi.org/10.1186/s12933-019-0828-y
|
[30]
|
Pitt, B. and Bhatt, D.L. (2021) Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes? Circulation, 144, 4-6. https://doi.org/10.1161/CIRCULATIONAHA.121.054442
|
[31]
|
Pitt, B., Steg, G., Leiter, L.A. and Bhatt, D.L. (2022) The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial In-farction in Patients with Type 2 Diabetes Mellitus. Cardiovascular Drugs and Therapy, 36, 561-567. https://doi.org/10.1007/s10557-021-07291-y
|
[32]
|
Lee, Y.T., Mohd Ismail, N.I. and Wei, L.K. (2021) Microbiome and Ischemic Stroke: A Systematic Review. PLOS ONE, 16, e0245038. https://doi.org/10.1371/journal.pone.0245038
|
[33]
|
Lin, N., Lin, H., Yang, Q., Lu, W., Sun, Z., Sun, S., Meng, L., Chi, J. and Guo, H. (2021) SGLT1 Inhibition Attenuates Apoptosis in Diabetic Cardiomyopathy via the JNK and p38 Pathway. Frontiers in Pharmacology, 11, Article ID: 598353. https://doi.org/10.3389/fphar.2020.598353
|
[34]
|
Li, Z., Agrawal, V., Ramratnam, M., Sharma, R.K., D’Auria, S., Sincoular, A., Jakubiak, M., Music, M.L., Kutschke, W.J., Huang, X.N., Gifford, L. and Ahmad, F. (2019) Cardiac Sodium-Dependent Glucose Cotransporter 1 Is a Novel Media-tor of Ischaemia/Reperfusion Injury. Cardiovascular Research, 115, 1646-1658.
https://doi.org/10.1093/cvr/cvz037
|
[35]
|
Seidelmann, S.B., Feofanova, E., Yu, B., Franceschini, N., Claggett, B., Kuokkanen, M., et al. (2018) Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk. Journal of the American College of Cardiology, 72, 1763-1773.
https://doi.org/10.1016/j.jacc.2018.07.061
|
[36]
|
Bhatt, D.L., Szarek, M., Steg, P.G., Cannon, C.P., Leiter, L.A., McGuire, D.K., et al. (2021) Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. The New Eng-land Journal of Medicine, 384, 117-128.
https://doi.org/10.1056/NEJMoa2030183
|
[37]
|
Bhatt, D.L., Szarek, M., Pitt, B., Cannon, C.P., Leiter, L.A., McGuire, D.K., et al. (2021) Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. The New England Journal of Medicine, 384, 129-139.
https://doi.org/10.1056/NEJMoa2030186
|
[38]
|
Ishida, N., Saito, M., Sato, S., Tezuka, Y., Sanbe, A., Taira, E. and Hirose, M. (2021) Mizagliflozin, a Selective SGLT1 Inhibitor, Improves Vascular Cognitive Impairment in a Mouse Model of Small Vessel Disease. Pharmacology Research & Perspectives, 9, e00869. https://doi.org/10.1002/prp2.869
|